MM

US-Cannabis Market is to grow by USD 46.90 billion between 2022 - 2027 | Rising millennial population Drive Demand for the market - Technavio

Retrieved on: 
Thursday, November 9, 2023
Aurora, Cannabis, Timeline of cannabis laws in the United States, Food, CBD, Millennials, ROW, Research, Geography, Software, Research report, Medical cannabis, Growth, Medical Marijuana, Inc., NIDA, Jazz Pharmaceuticals, MM, USD, National Institute on Drug Abuse, Compound annual growth rate, Drug, Retail

Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.

Key Points: 
  • Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.
  • Growth Prospects of the US Cannabis Market in Emerging Markets include:
    The emphasis on the medical potential of cannabis is propelling a surge in research and development.
  • As millennials drive demand, medical research advances and innovative trends emerge, the market is positioned for unparalleled expansion.
  • Cannabis-infused Edible Products Market: The global cannabis-infused edible products market share is expected to increase by USD 5,638.94 million from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 19.32%.

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Amplification, Rachel Haurwitz, IND, Acute myeloid leukemia, Patent, Food, Multiple myeloma, Infrared spectroscopy correlation table, CRISPR, MD, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Exercise, Drug development, Medicine, MM, Patient, Accounting, AML, Pharmaceutical industry, Vaccine, Management, Pfizer, Reindeer

BERKELEY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the third quarter of 2023 and reviewed recent business updates.

Key Points: 
  • CB-010 is an allogeneic anti-CD19 CAR-T cell therapy in development for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
  • CB-011: Caribou plans to provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances.
  • Appointed chief people officer: In September 2023, Caribou appointed Reigin Zawadzki to the newly created position of chief people officer.
  • Received $25.0 million Pfizer investment: In July 2023, Caribou announced that Pfizer invested $25.0 million in Caribou common shares on June 30, 2023.

EQS-News: Mayr-Melnhof Karton AG: MM reports results for the first three quarters of 2023

Retrieved on: 
Tuesday, November 7, 2023
Paper, Press release, Pressure, Report, Oswald, Plant, EUR, MM, Retail, Lithium, Lumber

At EUR 3,196.5 million, the Group's consolidated sales were below the previous year’s figure (1-3Q 2022: EUR 3,450.4 million).

Key Points: 
  • At EUR 3,196.5 million, the Group's consolidated sales were below the previous year’s figure (1-3Q 2022: EUR 3,450.4 million).
  • A primarily volume-related decline in the division MM Board & Paper contrasted with an acquisition- and price-related increase in the division MM Packaging.
  • Profit for the period amounted to EUR 27.9 million (2Q 2023: EUR 28.4 million; 3Q 2022: EUR 109.4 million).
  • MM Packaging's operating margin reached 11.4 % particularly as a result of declining cartonboard prices (2Q 2023: 8.6 %; 3Q 2022: 9.2 %).

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023
Adiponectin, Arm, University, American Association for the Study of Liver Diseases, Hepatology, Diabetes, II, Liver, C-reactive protein, CAP, Genotype, Lipid metabolism, Fibrosis, Metabolic syndrome, PNPLA3, Inflammation, Type 2 diabetes, HOMA-IR, Euronext Paris, Scan (company), Steatosis, NASH, Risk, Insulin, T2D, Abstract, Histology, Serum, MM, Insulin resistance, Adipose tissue, Patient, Fatty liver disease, Metabolism, Glucose, Medical device, Medical imaging, Pharmaceutical industry

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
ASH, MM, Half-life, Society, Therapy, Patient, BCMA, SAN, Vaccine

The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.

Key Points: 
  • The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.
  • ET, Presentation – 5:15 p.m. PT / 8:15 p.m.
  • ET
    The presentation will also be available on Harpoon’s website following the session.
  • For more details about the ASH Annual Meeting, please visit:

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, October 30, 2023
Week, DLBCL, FDA, Research, Research and development, NSCLC, Trial of the century, IND, DSM-IV codes, Food, Diabetes, Health Canada, G&A, BID, CRS, KRAS, Investment, R, NUP98, Glycated hemoglobin, CLL, CD135, Disease, Clinical trial, CRC, Cancer, QT interval, Menin, MM, FLT3, Safety, PDAC, Patient, FMS, Administration, AML, Mutation, Pharmaceutical industry, Medical imaging, Cryptocurrency, Osteopathic medicine in Canada

Both studies are now open for enrollment more than a quarter ahead of schedule.

Key Points: 
  • Both studies are now open for enrollment more than a quarter ahead of schedule.
  • Finally in this quarter, we also initiated the clinical study of our second, Biomea-discovered investigational covalent inhibitor, BMF-500, a novel FLT3 inhibitor.
  • Continued to advance development candidates derived from Biomea’s proprietary FUSION™ System platform to discover novel covalently binding small molecules.
  • G&A expenses were $17.1 million for the nine months ended September 30, 2023 compared to $15.2 million for the same period in 2022.

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Poster, Society, Abstract (summary), ASH, CD38, MM, Exposition, AbbVie, Safety, Lymphoid leukemia, Patient, American Society of Hematology, Lymphoma, Pharmaceutical industry, Hematology

Additionally, results from a phase 1/2 trial evaluating GEN3014 (HexaBody-CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM), will be presented.

Key Points: 
  • Additionally, results from a phase 1/2 trial evaluating GEN3014 (HexaBody-CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM), will be presented.
  • On Tuesday, December 12, at 11:00 AM EST (5:00 PM CET/4:00 PM GMT), Genmab will host its 2023 R&D Update and ASH Data Review.
  • Details, including the webcast link and registration will be available on www.genmab.com .
  • This meeting is not an official program of the ASH Annual Meeting.

Kiera DesChamps appointed as Senior Vice President of Business Development at Corporate Relocation International, (CRI)

Retrieved on: 
Friday, October 27, 2023
CRI, Ageing, Moves management, Business development, Creativity, Senior, Growth, Deschamps, MM, Management, Nursing

FLOWER MOUND, Texas, Oct. 27, 2023 /PRNewswire-PRWeb/ -- Corporate Relocation International, LLC (CRI) is thrilled to announce the appointment of Kiera DesChamps as the new Senior Vice President of Business Development for WellRive, CRI's Move Management (MM) division. An industry veteran who brings a wealth of experience and a proven track record of success, Kiera will play a pivotal role in driving growth and innovation for WellRive.

Key Points: 
  • Kiera DesChamps is appointed as Senior Vice President of Business Development for WellRive, a division of Corporate Relocation International (CRI), to leverage her extensive experience for expanding services in active adults and senior living transitions.
  • FLOWER MOUND, Texas, Oct. 27, 2023 /PRNewswire-PRWeb/ -- Corporate Relocation International, LLC (CRI) is thrilled to announce the appointment of Kiera DesChamps as the new Senior Vice President of Business Development for WellRive, CRI's Move Management (MM) division.
  • -Kiera DesChamps
    Kiera DesChamps, an esteemed leader in the Senior Move Management Industry, brings a wealth of experience and expertise to her new role at CRI.
  • Kiera comes to CRI from WayForth, where she served as Vice President of Business Development.

CMUV Bancorp Announces 2023 3rd Quarter Financial Results

Retrieved on: 
Friday, October 20, 2023
ACL, CVB, MM, Current Expected Credit Losses, Bank, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science

EL CENTRO, CA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – CMUV Bancorp, the holding company for Community Valley Bank (CVB), is pleased to announce unaudited 3rd Quarter results as of September 30, 2023.

Key Points: 
  • EL CENTRO, CA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – CMUV Bancorp, the holding company for Community Valley Bank (CVB), is pleased to announce unaudited 3rd Quarter results as of September 30, 2023.
  • During the 3rd quarter, net income totaled $991,000, which brought year-to-date net income to $2,873,863 through the first nine months of the year.
  • Net income for 3rd quarter equaled $0.54 per share.
  • For Quarter End September 30, 2023

Sexual Wellness Centers of America Awarded the First and Only Global Erectile Dysfunction Trademark Patent for its REGENmax Protocol that Reverses ED in 97% of men

Retrieved on: 
Tuesday, October 24, 2023
FDA, Trial of the century, Erectile dysfunction, Patent, Doctor of Philosophy, SWC, Research, ED, Male, Quality of life, Partnership, MM, Patient, Nursing

COLLEYVILLE, Texas, Oct. 24, 2023 /PRNewswire/ -- Sexual Wellness Centers of America (SWC) proudly announces its issuance and assignment of US patent number 11,806,301 for the world's first Erectile Dysfunction (ED) global trademark patent of its REGENmax protocol.

Key Points: 
  • COLLEYVILLE, Texas, Oct. 24, 2023 /PRNewswire/ -- Sexual Wellness Centers of America (SWC) proudly announces its issuance and assignment of US patent number 11,806,301 for the world's first Erectile Dysfunction (ED) global trademark patent of its REGENmax protocol.
  • Erectile dysfunction affects tens of millions of men worldwide, significantly impacting their quality of life and self-esteem.
  • The REGENmax protocol has solved the root causes of ED through a multi-faceted approach, with no need for pills or surgical intervention.
  • Sexual Wellness Centers of America now intends to extend the reach of its REGENmax protocol to the over 56 MM and growing men suffering from ED.